[
  {
    "ts": null,
    "headline": "How to invest in Turnarounds",
    "summary": "Investing in stocks going from bad to okay",
    "url": "https://finnhub.io/api/news?id=c108fbf7ee3e90f320ef358b3db263a224df48c5ec47c8557b8e4d78856ed01a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771237424,
      "headline": "How to invest in Turnarounds",
      "id": 139113455,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BDX",
      "source": "Yahoo",
      "summary": "Investing in stocks going from bad to okay",
      "url": "https://finnhub.io/api/news?id=c108fbf7ee3e90f320ef358b3db263a224df48c5ec47c8557b8e4d78856ed01a"
    }
  },
  {
    "ts": null,
    "headline": "5 Must-Read Analyst Questions From BD’s Q4 Earnings Call",
    "summary": "Becton, Dickinson and Company’s fourth quarter results were shaped by ongoing portfolio transformation, targeted investments in growth platforms, and the headwind of international tariffs. Management credited strong performance in biologic drug delivery, advanced tissue regeneration, and pharmacy automation, with CEO Thomas E. Polen highlighting \"broad-based growth across the markets where we have been doubling down on investments.\" However, persistent challenges in China and vaccine-related pre",
    "url": "https://finnhub.io/api/news?id=de09b052eb891b1310b9d56891661e7e5eec435492c062a8c8c1b619b64a1a13",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771219856,
      "headline": "5 Must-Read Analyst Questions From BD’s Q4 Earnings Call",
      "id": 139115900,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BDX",
      "source": "Yahoo",
      "summary": "Becton, Dickinson and Company’s fourth quarter results were shaped by ongoing portfolio transformation, targeted investments in growth platforms, and the headwind of international tariffs. Management credited strong performance in biologic drug delivery, advanced tissue regeneration, and pharmacy automation, with CEO Thomas E. Polen highlighting \"broad-based growth across the markets where we have been doubling down on investments.\" However, persistent challenges in China and vaccine-related pre",
      "url": "https://finnhub.io/api/news?id=de09b052eb891b1310b9d56891661e7e5eec435492c062a8c8c1b619b64a1a13"
    }
  }
]